TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Underestimated income to cost insured workers
  2. Tech companies lay claim to ‘Silicon Beach’
  3. Mini goes mainstream
  4. Data make strong case for 401(k)
  5. Health care law compliance complex for employers
  6. Trucking firms stretch to hire drivers
  7. GAO warns of health site weaknesses
  8. Good manners relevant when in professional setting
  9. Sometimes, all you need is a reboot
  10. Fired coal miners find employment in Wyoming
  11. ‘Airbender’ bent rules of Pa. film tax credit
Subscribe today! Click here for our subscription offers.